JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms

• Shuichi Shirane,
• Marito Araki,
• Soji Morishita,
• Yoko Edahiro,
• Hiraku Takei,
• Yongjin Yoo,
• Murim Choi,
• Yoshitaka Sunami,
• Yumi Hironaka,
• Masaaki Noguchi,
• Michiaki Koike,
• Naohiro Noda,
• Akimichi Ohsaka,
• Norio Komatsu

Affiliations

Shuichi Shirane

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan

Marito Araki

Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan

Soji Morishita

Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan

Yoko Edahiro

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan

Hiraku Takei

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan

Yongjin Yoo

Department of Biomedical Sciences, Seoul National University College of Medicine, Korea

Murim Choi

Department of Biomedical Sciences, Seoul National University College of Medicine, Korea

Yoshitaka Sunami

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan

Yumi Hironaka

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan

Masaaki Noguchi

Department of Hematology, Juntendo Urayasu Hospital, Chiba, Japan

Michiaki Koike

Department of Hematology, Juntendo Shizuoka Hospital, Japan

Naohiro Noda

Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan

Akimichi Ohsaka

Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan

Norio Komatsu

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan